Ph.D., Chief Scientific Officer, Abpro
Gavin MacBeath, PhD is currently the Chief Scientific Officer at Abpro, where he oversees antibody-based therapeutics programs focused on immuno-oncology, eye disease, and autoimmunity. At Abpro, Dr. MacBeath is combining their deep expertise in antibody generation with a suite of bispecific antibody engineering approaches to develop a broad pipeline of immune cell engagers, as well as molecules that modulate fibrosis and angiogenesis. Previously, Dr. MacBeath was a founder of Merrimack Pharmaceuticals, where he served as SVP of Discovery and Head of Translational Medicine (2010-2016). Prior to joining Merrimack, Dr. MacBeath served as faculty in the Department of Chemistry and Chemical Biology at Harvard University (2002-2010), most recently as Associate Professor. Dr. MacBeath holds a Bachelor of Science Degree in Genetics from the University of Manitoba, Canada (1991) and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, CA (1998).